Startseite Buprenorphine detection in biological samples
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Buprenorphine detection in biological samples

  • Nadia De Giovanni , Nadia Fucci , Salvatore Scarlata und Giovanni Donzelli
Veröffentlicht/Copyright: 21. September 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Buprenorphine is a narcotic analgesic used in the treatment of moderate-to-severe pain. In Italy, buprenorphine is now being used as an alternative in the therapeutic treatment of heroin abusers. Even if confirmation methods are needed for identification and quantitation, a rapid and sensitive test, such as an immunoassay, is essential for screening. We evaluated the Buprenorphine One-step ELISA test (designed for serum specimens) for the qualitative determination of buprenorphine in other matrices, such as urine, saliva and hair.


Corresponding author: Nadia De Giovanni, Istituto di Medicina Legale e delle Assicurazioni, Università Cattolica del Sacro Cuore, L.go Francesco Vito, 1, 00168 Rome, Italy Phone: +39-06-35507031, Fax: +39-06-35507033,

References

1. Auriemma F, Siconolfi M, Marguccio E, Esempio C, Stimolo R, Ferrante S, et al. Buprenorphine: our experience and differences compared with other drug addiction pharmacological therapies. Boll Farmacodip Alcoolis 2003; XXVI:15–8.Suche in Google Scholar

2. De Rosa MG, Biagiotti S, Sergi F, Baldoni A, Pierini C, Lumachini T, et al. Buprenorphine chloridrate in the treatment of opiate-dependence: a longitudinal study using bio-psycho-social clinical indicators. Boll Farmacodip Alcoolis 2002; XXV:32–8.Suche in Google Scholar

3. Nath RP, Upton RA, Everhart TE, Cheung P, Shwonek P, Jones RT, et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999; 39:619–23.10.1177/00912709922008236Suche in Google Scholar

4. Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD, Johnson RE, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20:369–78.10.1093/jat/20.6.369Suche in Google Scholar

5. Vincent F, Bessard J, Vacheron J, Mallaret M, Bessard G. Determination of buprenorphine and norbuprenorphine in urine and hair by GC/MS. J Anal Toxicol 1999; 23:270–9.10.1093/jat/23.4.270Suche in Google Scholar

6. Gopal S, Tzeng TB, Cowan A. Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma. Eur J Pharm Biopharm 2001; 51:147–51.10.1016/S0939-6411(00)00135-1Suche in Google Scholar

7. Cirimele V, Kintz P, Lhoner S, Ludes B. Evaluation of the microgenics buprenorphine urine assay versus LC-ES-MS. In: Proceedings of the 39th Annual International TIAFT Meeting, Aug 26–30, 2001, Prague, Czech Republic.Suche in Google Scholar

8. Cirimele V, Kintz P, Lohner S, Ludes B. Enzyme immunoassay validation for the detection of buprenorphine in urine. J Anal Toxicol 2003; 27,2:103–5.10.1093/jat/27.2.103Suche in Google Scholar PubMed

9. Cirimele V, Etienne S, Villain M, Ludes B, Kintz P. Evaluation of the one-step ELISA kit for the detection of buprenorphine in urine, blood and hair specimens. Forensic Sci Int 2004; 143:153–6.10.1016/j.forsciint.2004.02.035Suche in Google Scholar PubMed

10. Tracqui A. Kintz P, Mangin P. HPLC/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples J Forensic Sci 1997; 42:111–4.Suche in Google Scholar

11. De Giovanni N, Fucci N, Chiarotti M. Buprenorphine in saliva. Ann Toxicol Anal 2002; XIV:259.Suche in Google Scholar

Received: 2005-6-30
Accepted: 2005-9-27
Published Online: 2011-9-21
Published in Print: 2005-12-1

©2005 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Contents Volume 43, 2005
  2. Author Index
  3. Subject Index
  4. ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics
  5. Protein profiling as a diagnostic tool in clinical chemistry: a review
  6. Protein biochip systems for the clinical laboratory
  7. Automation of biochip array technology for quality results
  8. SELDI-TOF-MS proteomics of breast cancer
  9. Protein microarrays for the diagnosis of allergic diseases: state-of-the-art and future development
  10. Separation of human serum proteins using the Beckman-Coulter PF2D™ system: analysis of ion exchange-based first dimension chromatography
  11. Rapid, accurate genotyping of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 based on the use of denaturing HPLC
  12. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals
  13. Simple PCR heteroduplex, SSCP mutation screening methods for the detection of novel catalase mutations in Hungarian patients with type 2 diabetes mellitus
  14. Glycogen phosphorylase BB in acute coronary syndromes
  15. Alteration in serum leptin correlates with alterations in serum N-telopeptide of collagen type I and serum osteocalcin during the progression of osteoporosis in ovariectomized rats
  16. Glycemic control in diabetes in three Danish counties
  17. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells
  18. Buprenorphine detection in biological samples
  19. The effect of thyroid antibody positivity on reference intervals for thyroid stimulating hormone (TSH) and free thyroxine (FT4) in an aged population
  20. High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation
  21. Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex® Multiplex technology
  22. Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis
  23. Acknowledgement
Heruntergeladen am 12.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2005.235/html
Button zum nach oben scrollen